Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

INTRODUCTION: Patients with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR)-activating mutations have good response rate and longer progression-free survival (PFS) when treated with the tyrosine kinase inhibitors (TKI) compared with platinum-based chemotherapy. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Chih-Yen, Chen, Chuan-Mu, Liao, Wei-Chih, Wu, Biing-Ru, Chen, Chih-Yu, Chen, Wei-Chun, Hsia, Te-Chun, Cheng, Wen-Chien, Chen, Chia-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966263/
https://www.ncbi.nlm.nih.gov/pubmed/29849936
http://dx.doi.org/10.18632/oncotarget.24386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966263/
https://www.ncbi.nlm.nih.gov/pubmed/29849936
http://dx.doi.org/10.18632/oncotarget.24386

Ejemplares similares